Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings

5 Analysts Have This to Say About Jazz Pharmaceuticals

By Benzinga Insights
Today, 2:18 AM
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter:

JAZZ

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News
  • Penny Stocks
  • Small Cap

Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan
Today, 2:18 AM
The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA)…

AGLE

Read More
2 minute read
  • Cannabis
  • Markets
  • News

Jazz’ Epidiolex, The Only FDA-Approved CBD Drug, Enters Phase 3 Trial Evaluating Its Effects In Patients With Myoclonic-Atonic Seizures

By Vuk Zdinjak
Today, 2:18 AM
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has initiated a new Phase 3 trial to investigate the efficacy and safety of Epidiolex (cannabidiol), known as Epidyolex in Europe, in children and adolescents with e

JAZZ

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • News

Jazz Pharmaceuticals Announces Initiation Of Phase 3 Trial Evaluating Epidiolex/Epidyolex For Patients With Epilepsy With Myoclonic-Atonic Seizures

By Bill Haddad
Today, 2:18 AM
Trial is the first randomized, controlled clinical trial evaluating cannabidiol to treat children and adolescents living with a developmental and epileptic encephalopathy known as Epilepsy with

JAZZ

Read More
1 minute read
  • Cannabis
  • General
  • Markets
  • News
  • Politics

‘North Dakota Voters Will Decide On Marijuana Legalization At The Ballot This November, State Certifies’ -Marijuana Moment Report

By Benzinga Newsdesk
Today, 2:18 AM
https://www.marijuanamoment.net/north-dakota-voters-will-decide-on-marijuana-legalization-at-the-ballot-this-november-state-certifies/

ACB

Read More
1 minute read
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • News
  • Price Target

‘Street Underestimates Jazz Pharma’s Cash-Flow’ Says This Analyst

By Vandana Singh
Today, 2:18 AM
HC Wainwright tweaked the price target on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $204 with a reiterated Buy rating on slightly increased forward…

JAZZ

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

BMO Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $188

By Benzinga Newsdesk
Today, 2:18 AM
BMO Capital analyst Gary Nachman maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price target from $185 to $188.

JAZZ

Read More
1 minute read
  • Cannabis
  • General
  • Markets
  • Politics

‘Booker Says There’s Republican Support For ‘SAFE Banking Plus’ Marijuana Compromise’ -Marijuana Moment Report

By Benzinga Newsdesk
Today, 2:18 AM
https://www.marijuanamoment.net/booker-says-theres-republican-support-for-safe-banking-plus-marijuana-compromise/

ACB

Read More
1 minute read
  • News

Politico Reporter Tweets: Congress appears ready to send the first-ever cannabis bill to POTUS’ desk

By Charles Gross
Today, 2:18 AM
https://twitter.com/natsfert/status/1550187086342369280

ACB

Read More
1 minute read
  • Cannabis
  • General
  • Markets
  • Politics

‘D.C. Mayor Signs Bill Providing Workplace Protections For Marijuana Consumers’ -Marijuana Moment Report

By Benzinga Newsdesk
Today, 2:18 AM
https://www.marijuanamoment.net/d-c-mayor-signs-bill-providing-workplace-protections-for-marijuana-consumers/

ACB

Posts navigation

Previous 1 … 3 4 5 … 18 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service